U.S. accuses Novartis of transplant drug kickbacks

04/23/2013 | PharmaLive.com · Wall Street Journal, The

The U.S. Department of Justice has filed a lawsuit against the U.S. arm of Swiss firm Novartis alleging a kickback scheme using rebates and discounts to pharmacies to switch transplant patients to the company's Myfortic immunosuppressant treatment. By hiding these arrangements, "Novartis caused the public to pay tens of millions of dollars for kickback-tainted drugs that were dispensed by pharmacists" in partnership with the drugmaker, said U.S. Attorney Preet Bharara. Novartis is already subject to a five-year Corporate Integrity Agreement to resolve charges of improperly promoting its Trileptal epilepsy drug and several other medications. A representative for Novartis says it plans to dispute the new charges.

View Full Article in:

PharmaLive.com · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA